GRACE: An open-label, multicenter trial to compare the efficacy, safety, and tolerability of PREZISTA (darunavir)/ritonavir by gender and race, when administered in combination with an individually optimized background regimen over a 48-week treatment period

Trial Profile

GRACE: An open-label, multicenter trial to compare the efficacy, safety, and tolerability of PREZISTA (darunavir)/ritonavir by gender and race, when administered in combination with an individually optimized background regimen over a 48-week treatment period

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2014

At a glance

  • Drugs Darunavir (Primary) ; Antiretrovirals; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GRACE
  • Sponsors Tibotec Inc
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Sep 2010 Data from GRACE will be published in the September 21st issue of the Annals of Internal Medicine, according to a Tibotec Therapeutics media release.
    • 21 Sep 2010 Results published in Annals of Internal Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top